Sign in →

Test Code MAFP1 Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum


Necessary Information


In order to provide the best results, either answer the order entry questions or provide the required information using the Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595).



Specimen Required


Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Do not collect specimen after amniocentesis as this could affect results.

2. Centrifuge and aliquot serum into plastic vial within 2 hours of collection.

Additional Information:

1. Collect blood between 15 weeks, 0 days and 22 weeks, 6 days.

2. Initial or repeat testing is determined in the laboratory at the time of report and will be reported accordingly. To be considered a repeat test for the patient, the testing must be within the same pregnancy and trimester, with interpretable results for the same test, and both tests are performed at Mayo Clinic.


Forms

1. Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595) is required

2. If not ordering electronically, complete, print, and send a General Request (T239)

Useful For

Prenatal screening for open neural tube defect

Method Name

Two-Site Immunoenzymatic (Sandwich) Assay

Reporting Name

AFP Single Marker SCRN, Maternal, S

Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  90 days
  Ambient  7 days

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus OK

Clinical Information

Alpha-fetoprotein (AFP) is a fetal protein that is initially produced in the fetal yolk sac and liver. A small amount is produced by the gastrointestinal tract. By the end of the first trimester, nearly all AFP is produced by the fetal liver. The concentration of AFP peaks in fetal serum between 10 to 13 weeks. Fetal AFP diffuses across the placental barrier into the maternal circulation. A small amount also is transported from the amniotic cavity.

 

The AFP concentration in maternal serum rises throughout pregnancy, from the nonpregnancy level of 0.2 ng/mL to about 250 ng/mL at 32 weeks gestation. If the fetus has an open neural tube defect (NTD), AFP is thought to leak directly into the amniotic fluid causing unexpectedly high concentrations of AFP. Subsequently, the AFP reaches the maternal circulation, producing elevated serum levels. Other fetal abnormalities such as omphalocele, gastroschisis, congenital kidney disease, esophageal atresia, and other fetal distress situations (eg, threatened abortion and fetal demise) also may result in maternal serum AFP elevations. Increased maternal serum AFP concentrations also may be seen in multiple pregnancies and in unaffected singleton pregnancies in which the gestational age has been underestimated.

 

Lower maternal serum AFP concentrations have been associated with an increased risk for genetic conditions such as trisomy 21 (Down syndrome) and trisomy 18 (Edwards syndrome). Risks for these syndrome disorders are only provided with the use of multiple marker screening (QUAD1 / Quad Screen [Second Trimester] Maternal, Serum).

 

Measurement of maternal serum AFP values is a standard tool used in obstetrical care to identify pregnancies that may have an increased risk for NTD. The screen is performed by measuring AFP in maternal serum and comparing this value to the median AFP value in an unaffected population to obtain a multiple of the median (MoM). The laboratory has established a MoM cutoff of 2.5, which classifies each screen as either screen-positive or screen-negative. A screen-positive result indicates that the value obtained exceeds the established cutoff. A positive screen does not provide a diagnosis but indicates that further evaluation should be considered.

Reference Values

NEURAL TUBE DEFECTS:

An alpha-fetoprotein (AFP) multiple of the median (MoM) <2.5 is reported as screen negative.

AFP MoM ≥2.5 (singleton and twin pregnancies) are reported as screen positive.

 

An interpretive report will be provided.

Day(s) Performed

Monday through Friday

Report Available

4 to 6 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

82105